Hypofibrinogenemia induced by orelabrutinib
10.3760/cma.j.cn114015-20220119-00060
- VernacularTitle:奥布替尼致低纤维蛋白原血症
- Author:
Lina ZHANG
1
;
Wei FANG
1
;
Jinfeng LI
1
;
Jian GAO
1
;
Bing WANG
1
Author Information
1. 威海市立医院药剂科，威海 264200
- Publication Type:Journal Article
- Keywords:
Afibrinogenemia;
Orelabrutinib
- From:
Adverse Drug Reactions Journal
2022;24(9):492-494
- CountryChina
- Language:Chinese
-
Abstract:
A 78-year-old female patient was treated with orelabrutinib 100 mg once daily orally due to recurrence of lymphoma. On the 2nd day of treatment, the patient′s fecal occult blood was weakly positive. Three days later, fibrinogen was 0.61 g/L. After intravenous infusion of cryoprecipitated coagulation factor and frozen plasma, the fibrinogen level rose slightly. The patient did not follow the doctor′s advice and took orelabrutinib irregularly, and her fibrinogen level recovered to 1.71 g/L. After further regular treatment with orelabrutinib, her fibrinogen decreased to 0.74 g/L and irregular skin ecchymosis and bleeding spots appeared in the inner side skin of both lower limbs. The fibrinogen in the patient returned to 2.17 g/L after temporary suspension of orelabrutinib and receiving 2 times of intravenous infusion of cold precipitated coagulation factor 10 U, then decreased to 0.94 g/L after reuse of orelabrutinib, and finally recovered to 3.82 g/L after 3 times of intermittent infusion of cold precipitated coagulation factor. It is considered that the hypofibrinogenemia in the patient was caused by orelabrutinib.
